MedTrace Logo

To Evaluate the Efficacy and Safety of 'BRDE33-100' for the Temporary Correction of Moderate to Severe Nasolabial Folds

NCT07069920 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2025-07-17

No results posted yet for this study

Summary

This study aims to demonstrate the non-inferiority of BRDE33-100 to Soonsoofill in temporarily improving moderate to severe nasolabial folds.

Conditions

  • Nasolabial Folds

Interventions

DEVICE

BRDE33-100

BRDE33-100 will be injected once at Visit 2 (Baseline).

DEVICE

Soonsoofill

Soonsoofill will be injected once at Visit 2 (Baseline).

Sponsors & Collaborators

  • BRPharm Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jiye Kim, M.D., PhD · Wonju Severance Christian Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-14
Primary Completion
2025-06-25
Completion
2026-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07069920 on ClinicalTrials.gov